ReviewDrug design, development and therapy2018
An insight into new strategies to combat antifungal drug resistance.
Review in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Unravelling azole resistance in fungal pathogens: molecular mechanisms, diagnostic challenges, and therapeutic strategies.World journal of microbiology & biotechnology · 2025Review
- Disruption of the ATP-dependent unfoldase ClpX reverses antifungal resistance in Cryptococcus neoformans.Nature communications · 2025Article
- Anionic lipids direct efficient microfluidic encapsulation of stable and functionally active proteins in lipid nanoparticles.Communications materials · 2025Article
- Understanding the clinical and environmental drivers of antifungal resistance in the One Health context.Microbiology (Reading, England) · 2024Review
- Potential Activity of Micafungin and Amphotericin B Co-Encapsulated in Nanoemulsion against SystemicJournal of fungi (Basel, Switzerland) · 2024Article
- Old and new strategies in therapy and diagnosis against fungal infections.Applied microbiology and biotechnology · 2024Review
- Studies on Antifungal Properties of Methacrylamido Propyl Trimethyl Ammonium Chloride Polycations and Their ToxicityMicrobiology spectrum · 2023Article
- DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs.Advanced drug delivery reviews · 2023Review
- Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2023Review
- Fungal arthritis: A challenging clinical entity.World journal of orthopedics · 2023Review
- Antifungal Activity of a Library of Aminothioxanthones.Antibiotics (Basel, Switzerland) · 2022Article
- Molecular Mapping of Antifungal Mechanisms Accessing Biomaterials and New Agents to Target Oral Candidiasis.International journal of molecular sciences · 2022Review
- DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis.Antimicrobial agents and chemotherapy · 2022Article
- Green Synthesis of Silver Nanoparticles Using theACS omega · 2021Article
- Marine-Derived Compounds and Prospects for Their Antifungal Application.Molecules (Basel, Switzerland) · 2020Review
- Targeting intrinsic cell death pathways to control fungal pathogens.Biochemical pharmacology · 2019Review
- Perspectives of Phage Therapy in Non-bacterial Infections.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal infections especially in immunocompromised patients represent a dominating cause of mortality. The most commonly used antifungal agents can be divided into three broad categories, including triazoles, echinocandins and polyenes. Antifungal resistance is on the increase, posing a growing threat to the stewardship of immunocompromised patients with fungal infections. The paucity of currently available antifungals leads to the rapid emergence of drug resistance and thus aggravates the refractoriness of invasive fungal infections. Therefore, deep exploration into mechanisms of drug resistance and search for new antifungal targets are required. This review highlights the therapeutic strategies targeting Hsp90, calcineurin, trehalose biosynthesis and sphingolipids biosynthesis, in an attempt to provide clinical evidence for overcoming drug resistance and to form the rationale for combination therapy of conventional antifungals and agents with novel mechanisms of action. What's more, this review also gives a concise introduction of three new-fashioned antifungals, including carboxymethyl chitosan, silver nanoparticles and chromogranin A-N46.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.